Incyte | INCY - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agenus USD 38.52M 3.2M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amgen USD 541M 1000K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Exelixis USD 248.88M 4.82M 2026-06
Gilead Sciences USD 1.24B 1000K 2026-06
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
MacroGenics USD 63.56M 241K 2026-03
Merck USD 2.47B 4.93M 2026-03
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Novartis USD 1.9B 7.38M 2026-06
Novartis USD 1.91B 60K 2026-03
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06